To Compare the PK, PD, Safety & Immunogenicity of ADL-018 Lyo in Healthy Adult Subjects
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This will be a randomized, double blind, two-arm, single dose, parallel group, PK, PD and
safety and immunogenicity study in healthy, adult, subjects.
Total 204 healthy, adult, eligible human subjects (102 in each treatment arm) will be
enrolled in the study with their consent. Required *standby subjects will also be enrolled to
ensure that 204 subjects are dosed in the study.
The study will be conducted in cohorts; all the study procedures will be identical as
mentioned in the protocol for all the cohorts.